Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…
Sponsor: NRG Oncology
NCT ID: NCT07166406
Locations: - Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California
- Palo Alto Medical Foundation-Fremont — Fremont, California
+ 135 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Locations: - Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
- Research Site — Los Angeles, California
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Yale University - New Haven Hospital - Yale Cancer Center — New Haven, Connecticut
+ 14 more sites in the U.S.
Phase 2, Phase 3 Recruiting Academic/Other
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition…
Sponsor: Inova Health Care Services
NCT ID: NCT06007846
Locations: - Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Health Care Service — Falls Church, Virginia
Phase 3 Recruiting Industry
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namode…
Sponsor: Can-Fite BioPharma
NCT ID: NCT05201404
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either…
Sponsor: Pfizer
NCT ID: NCT07227012
Locations: - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California
- UCI Health - Irvine — Irvine, California
+ 43 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Locations: - Helios Clinical Research — Cerritos, California
- California Research Institute — Los Angeles, California
- Sharp Memorial Hospital — San Diego, California
+ 32 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Locations: - Mayo Clinic — Phoenix, Arizona
- Honor Health — Scottsdale, Arizona
- Arizona Cancer Center at University of Arizona — Tucson, Arizona
+ 28 more sites in the U.S.
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Locations: - Precision NextGen Oncology & Research Center — Beverly Hills, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- University of California Los Angeles Rheumatology — Westwood, Los Angeles, California
+ 27 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Locations: - Research Site 111 — Tucson, Arizona
- Research Site 125 — Los Angeles, California
- Research Site 133 — Los Angeles, California
+ 25 more sites in the U.S.
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
+ 18 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…
Sponsor: Tvardi Therapeutics, Incorporated
NCT ID: NCT05440708
Locations: - The Kirklin Clinic of University of Alabama Birmingham Hospital — Birmingham, Alabama
- University of California San Diego — La Jolla, California
- Norris Comprehensive Cancer Center — Los Angeles, California
+ 18 more sites in the U.S.